DAFTAR PUSTAKA

Amer, M. H. (2013). Cancer-associated thrombosis: Clinical presentation and survival. *Cancer Management and Research*, *5*(1), 165–178. https://doi.org/10.2147/CMAR.S47094

Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., Meyer, L., Gress, D. M., Byrd, D. R., & Winchester, D. P. (2017). The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging . *CA: A Cancer Journal for Clinicians*, *67*(2), 93–99. https://doi.org/10.3322/caac.21388

Barcellona, D., Fenu, L., & Francesco, M. (2017). Point-of-care Testing INR: An Overview. *Clinical Chemistry and Laboratory Medicine (CCLM)*, *55*(6), 800–805.

Blom, J. W., Osanto, S., & Rosendaal, F. R. (2004). The risk of a venous thrombotic event in lung cancer patients: Higher risk for adenocarcinoma than squamous cell carcinoma. *Journal of Thrombosis and Haemostasis*, *2*(10), 1760–1765. https://doi.org/10.1111/j.1538-7836.2004.00928.x

Connolly, G. C., & Francis, C. W. (2013). Cancer-associated thrombosis. *American Society of Hematology*, 684–691.

de Groot, P. M., Wu, C. C., Carter, B. W., & Munden, R. F. (2018). The epidemiology of lung cancer. In *Translational Lung Cancer Research* (Vol. 7, Issue 3, pp. 220–233). AME Publishing Company. https://doi.org/10.21037/tlcr.2018.05.06

Di, W., Xu, H., Xue, T., & Ling, C. (2021). Advances in the prediction and risk assessment of lung cancer-associated venous thromboembolism. *Cancer Management and Research*, *13*, 8317–8327. https://doi.org/10.2147/CMAR.S328918

GLOBOCAN. (2021). Indonesia. *The Global Cancer Observatory*, *1*(1), 1–2.

Guo, J., Gao, Y., Gong, Z., Dong, P., Mao, Y., Li, F., Rong, J., Zhang, J., Zhou, Y., Feng, H., Guo, H., Gu, L., An, M., Wen, K., & Zhang, J. (2021). Plasma D-Dimer Level Correlates with Age, Metastasis, Recurrence, Tumor-Node-Metastasis Classification (TNM), and Treatment of Non-Small-Cell Lung Cancer (NSCLC) Patients. *BioMed Research International*, *2021*, 1–12. https://doi.org/10.1155/2021/9623571

Harlivasari, A. D., & Syahruddin, E. (2019). Hiperkoagulasi pada Kanker Paru. *Jurnal Respirologi Indonesia*, *39*(2), 130–139.

Hiraki, T., Gobara, H., Fujiwara, H., Ishii, H., Tomita, K., Uka, M., Makimoto, S., & Kanazawa, S. (2013). Lung cancer ablation: Complications. *Seminars in Interventional Radiology*, *30*(2), 169–175. https://doi.org/10.1055/s-0033-1342958

Jin, Y. F., Ye, Y. Q., Jin, Y. J., Zhu, X. Y., Sha, M., Liu, R., & Chen, C. (2022). Risk Factors and Impact on Outcomes of Lung Cancer Patients Concurrent with Deep Vein Thrombosis. *Cancer Control*, *29*, 1–8. https://doi.org/10.1177/10732748221145074

Kanwal, M., Ding, X. J., & Cao, Y. (2017). Familial risk for lung cancer. In *Oncology Letters* (Vol. 13, Issue 2, pp. 535–542). Spandidos Publications. https://doi.org/10.3892/ol.2016.5518

Kementerian Kesehatan RI. (2018). *Pedoman Pengendalian Faktor Risiko Kanker Paru* (1st ed., Vol. 1). Kementerian Kesehatan Republik Indonesia.

Komurcuoglu, B., Ulusoy, S., Gayaf, M., Guler, A., & Ozden, E. (2011). Prognostic value of plasma D-dimer levels in lung carcinoma. *Tumori*, *97*(6), 743–748. https://doi.org/10.1700/1018.11091

Kumar, V., Abbas, A., & Aster, J. (2017). *Robbins Basic Pathology* (10th ed.). Elsevier.

Levy, J. H., Szlam, F., Wolberg, A. S., & Winkler, A. (2014). Clinical use of the activated partial thromboplastin time and prothrombin time for screening: A review of the literature and current guidelines for testing. In *Clinics in Laboratory Medicine* (Vol. 34, Issue 3, pp. 453–477). W.B. Saunders. https://doi.org/10.1016/j.cll.2014.06.005

Liaqat, A., Farooq, A., Gulzar, Q., Stalcup, S., & Abdalsalam, B. (2021). Central Vein Thrombosis in Pulmonary Neuroendocrine Neoplasm: A Novel Presentation. *Cureus*. https://doi.org/10.7759/cureus.16499

Loizou, E., Mayhew, D. J., Martlew, V., & Murthy, B. V. S. (2018). Implications of deranged activated partial thromboplastin time for anaesthesia and surgery. In *Anaesthesia* (Vol. 73, Issue 12, pp. 1557–1563). Blackwell Publishing Ltd. https://doi.org/10.1111/anae.14344

Majidiah, F., Sjahruddin, E., & Andarini, S. L. (2014). Trombosis Vena Dalam pada Pasien Kanker Paru Berdasar Kriteria Wells. *J Respir Indo*, *34*(1), 1–10.

Maraz, A., Furak, J., Varga, Z., Kahan, Z., Tiszlavicz, L., & Hideghety, K. (2013). Thrombocytosis Has a Negative Prognostic Value in Lung Cancer. *Anticancer Research*, *33*, 1725–1730.

May, L., Shows, K., Nana-Sinkam, P., Li, H., & Landry, J. W. (2023). Sex Differences in Lung Cancer. *Cancers*, *15*(12), 1–20. https://doi.org/10.3390/cancers15123111

Mohan, H. (2014). *Textbook of Pathology* (7th ed.). Jaypee Brothers Medical Publisher.

Nabila, S. F., Putra, D. S., Farlinda, S., & Ardianto, E. T. (2021). Analisis Faktor Risiko pada Penyakit Karsinoma Paru (C34) Pasien Rawat Inap di Rumah Sakit Baladhika Husada Jember. *J-REMI: Jurnal Rekam Medik Dan Informasi Kesehatan*, *2*(2), 244–254.

Navi, B. B., Reiner, A. S., Kamel, H., Iadecola, C., Okin, P. M., Elkind, M. S. V., Panageas, K. S., & DeAngelis, L. M. (2017). Risk of Arterial Thromboembolism in Patients With Cancer. *Journal of the American College of Cardiology*, *70*(8), 926–938. https://doi.org/10.1016/j.jacc.2017.06.047

PDPI. (2021). Panduan Umum Praktik Klinis Penyakit Paru dan Pernapasan. *Perhimpunan Dokter Paru Indonesia*, *1*(1), 225.

Razak, N. B. A., Jones, G., Bhandari, M., Berndt, M. C., & Metharom, P. (2018). Cancer-associated thrombosis: An overview of mechanisms, risk factors, and treatment. In *Cancers* (Vol. 10, Issue 10, pp. 1–21). MDPI AG. https://doi.org/10.3390/cancers10100380

Rediputra, A. (2013). Peran Pemeriksaan D-Dimer terhadap Diagnosis Trombosis. *RSUD Kabupaten Pesawaran*, *1*(1), 436–453.

Samosir, G. M., Siagian, P., & Eyanoer, P. C. (2018). Korelasi Faal Hemostasis dengan Tumor Marker pada Pasien Kanker Paru Bukan Sel Kecil dengan Kemoterapi. *J Respir Indo*, *38*(1), 33–38.

Sanikini, H., Yuan, J.-M., Butler, L. M., Koh, W.-P., Gao, Y.-T., Steffen, A., Johansson, M., Vineis, P., Goodman, G. E., Barnett, M. J., Hung, R. J., Chen, C., & Stücker, I. (2018). Body mass index and lung cancer risk: a pooled analysis based on nested case-control studies from four cohort studies. *BMC Cancer*, *18*(220), 1–10. https://doi.org/10.1186/s12885-018-4124-0

Sherwood, L. (2013). *Introduction to Human Physiology* (8th ed.). Cole Cengage Learning.

Sinaga, F. T., Oktobiannobel, J., Soemarwoto, R. A., & Yunanda, V. (2022). Gambaran Progresivitas dan Prognosis pada Pasien CA Paru di RSUD Dr. H. Abdoel Moeloek Provinsi Lampung Tahun 2018-2021. *Medula*, *12*(2), 336–341.

Siregar, Y. S., Widyaningsih, W., & Syahruddin, E. (2016). Indeks Massa Tubuh, Presentase Otot Rangka dan Albumin pada Pasien Kanker Paru Karsinoma Bukan Sel Kecil Sebelum dan Setelah Kemoterapi. *J Respir Indo*, *36*(2), 73–82.

St Pierre, B. P., & Edwin, S. B. (2019). Assessment of Anticoagulation in Patients Receiving Ultrasound-Assisted Catheter-Directed Thrombolysis for Treatment of Pulmonary Embolism. *Ann Pharmacother*, *53*(5), 453–457.

Sukrisman, L. (2020). Dapatkah D-dimer Digunakan sebagai Penanda Koagulasi pada Kanker? *Jurnal Penyakit Dalam Indonesia*, *7*(1), 1.

Sutandyo, N., & Setiawan, L. (2020). Perubahan Status Koagulasi Pasien Kanker Padat Pasca Kemoterapi di Indonesia: Sebuah Studi Prospektif. *Jurnal Penyakit Dalam Indonesia*, *7*(1), 2–7. https://doi.org/10.7454/jpdi.v7i1.387

Travis, W. D., Brambilla, E., Nicholson, A. G., Yatabe, Y., Austin, J. H. M., Beasley, M. B., Chirieac, L. R., Dacic, S., Duhig, E., Flieder, D. B., Geisinger, K., Hirsch, F. R., Ishikawa, Y., Kerr, K. M., Noguchi, M., Pelosi, G., Powell, C. A., Tsao, M. S., & Wistuba, I. (2015). The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances since the 2004 Classification. In *Journal of Thoracic Oncology* (Vol. 10, Issue 9, pp. 1243–1260). Elsevier Inc. https://doi.org/10.1097/JTO.0000000000000630

Tuzovic, M., Herrmann, J., Iliescu, C., Marmagkiolis, K., Ziaeian, B., & Yang, E. H. (2018). Arterial Thrombosis in Patients with Cancer. In *Current Treatment Options in Cardiovascular Medicine* (Vol. 20, Issue 5). Springer Healthcare. https://doi.org/10.1007/s11936-018-0635-x

Venuta, F., Diso, D., Onorati, I., Anile, M., Mantovani, S., & Rendina, E. A. (2016). Lung cancer in elderly patients. *Journal of Thoracic Disease*, *8*(S11), S908–S914. https://doi.org/10.21037/jtd.2016.05.20

Vitale, C., D'Amato, M., Calabrò, P., Stanziola, A. A., Mormile, M., & Molino, A. (2015). Venous thromboembolism and lung cancer: A review. *Multidisciplinary Respiratory Medicine*, *10*(1). https://doi.org/10.1186/s40248-015-0021-4

Walker, A. J., Baldwin, D. R., Card, T. R., Powell, H. A., Hubbard, R. B., & Grainge, M. J. (2016). Risk of venous thromboembolism in people with lung

cancer: A cohort study using linked UK healthcare data. *British Journal of Cancer*, *115*(1), 115–121. https://doi.org/10.1038/bjc.2016.143

Wang, Y., & Wang, Z. (2015). Predictive Value of Plasma D-Dimer Levels in Patients with Advanced Non-Small-Cell Lung Cancer. *OncoTargets and Therapy*, *8*, 805–808. https://doi.org/10.2147/OTT.S78154